Phil Vick­ers talks new role as head of Long­wood’s Solu af­ter Faze shut­down; Re­gen­eron CFO to re­tire in Feb­ru­ary

Phil Vick­ers start­ed last week as pres­i­dent and CEO of Solu Ther­a­peu­tics, a Long­wood Fund start­up de­vel­op­ing small mol­e­cule-an­ti­body chimeras.

He takes the place of Long­wood ex­ec­u­tive part­ner David Don­abe­di­an, who has tak­en the ear­ly CEO roles at a num­ber of com­pa­nies Long­wood has backed, in­clud­ing Ax­i­al Ther­a­peu­tics, Im­muneID and DEM Bio­Phar­ma.

Vick­ers was pre­vi­ous­ly head of Faze Med­i­cines, a con­den­sates biotech start­ed by Third Rock that launched with $81 mil­lion in 2020 be­fore shut­ting down at the end of last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.